Resting Full-cycle Ratio (RFR)-Guided Revascularization

Sponsor
Sejong General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT06075160
Collaborator
Wonju Severance Christian Hospital (Other), Hospital San Carlos, Madrid (Other), Seoul St. Mary's Hospital (Other), Dong-A University Hospital (Other), Gyeongsang National University Hospital (Other), Soon Chun Hyang University (Other), Keimyung University Dongsan Medical Center (Other), Ulsan University Hospital (Other), Seoul National University Bundang Hospital (Other), Kosin University Gospel Hospital (Other), Pusan National University Hospital (Other)
1,167
1
53.2
22

Study Details

Study Description

Brief Summary

The purpose of this study is to compare the clinical outcomes of a 2-year follow-up to determine whether RFR-guided coronary intervention is non-inferior to FFR-guided coronary intervention in patients with intermediate coronary stenosis.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Resting full-cycle ratio (RFR)-guided revascularization
  • Diagnostic Test: Fractional flow ratio (FFR)-guided revascularization

Detailed Description

Myocardial ischemia is a key determinant of clinical prognosis in patients with coronary artery disease. In this regard, functional assessment of intermediate coronary stenoses with transtenotic pressure ratios provides a more accurate measure of stenosis-derived myocardial ischemia in comparison to conventional coronary angiography (3-5). One of the major clinical benefit of fractional flow reserve (FFR) is that, by acting as a gatekeeper, non-ischemia-causing lesions suitable for optimal medical treatment can be accurately identified, avoiding unnecessary coronary stenting. However, despite being support with the highest level of recommendation by the current guidelines for guiding clinical-decision making, adoption of FFR in the real world practice is still very low, mainly due to the need of hyperemic agents like adenosine that frequently cause patient discomfort, and time consumption. To overcome such limitations of pressure-wire derived index from the need of adenosine, other alternatives have been looking for over the last years. Instantaneous wave-free ratio (iFR), a resting trans-stenotic pressure index obtained as the ratio of distal coronary pressure to aortic pressure during the diastolic wave-free period, demonstrated a good diagnostic accuracy to define functional significance of coronary lesions without need of adenosine, using FFR as reference. Recently, two large, randomized trials demonstrated that iFR-guided coronary revascularization is clinically non-inferior to FFR-guided revascularization with respect to one-year risk of major adverse cardiac events. Accordingly, like FFR, iFR is now receiving the highest level of recommendations to guide clinical decision making in patients with stable intermediate coronary stenosis. A new adenosine-free index, the resting full-cycle ratio (RFR), has recently emerged. RFR is defined as the lowest ratio of intracoronary distal pressure to aortic pressure under resting condition, irrespective of systole or diastole, and has demonstrated equivalent diagnostic performance to iFR. RFR has an advantage over iFR, because it is not limited by sensitive land marking of components of the pressure waveform unlike iFR.

This novel physiologic index without the need of adenosine has the potential to increase the worldwide adoption of coronary physiology in guiding coronary revascularization in daily clinical practice. However, there is a paucity of important data regarding clinical outcomes of RFR-guided revascularization strategy. We hypothesize long-term clinical outcome of RFR-guided revascularization is non-inferior to that of FFR-guided revascularization, and it reduce the rate of PCI than FFR-guided revascularization. Therefore, we sought to investigate the long-term effectiveness and safety of RFR-based decision making in patients with one or more intermediate coronary stenosis, and to assess whether it is non-inferior to FFR-guided revascularization.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
1167 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prospective Evaluation of Long-term Clinical Outcomes After Resting Full-cycle Ratio (RFR)-Guided Percutaneous Coronary Revascularization; A Multi-center, International, Single Arm Interventional, Comparing Registry (COMFORT Study)
Actual Study Start Date :
Jul 27, 2022
Anticipated Primary Completion Date :
Dec 31, 2026
Anticipated Study Completion Date :
Dec 31, 2026

Outcome Measures

Primary Outcome Measures

  1. A composite of death from any cause, non-fatal myocardial infarction, or unplanned revascularization [At 2-year]

Secondary Outcome Measures

  1. Target lesion failure [At 2-year]

    A composite of cardiac death, target vessel MI, or target lesion revascularization

  2. Target vessel failure [At 2-year]

    A composite of cardiac death, target vessel MI, or target vessel revascularization

  3. Death from any cause [At 2-year]

  4. Cardiovascular death [At 2-year]

  5. Cardiac death or non-fatal MI [At 2-year]

  6. Non-fatal MI [At 2-year]

  7. Any unplanned revascularization [At 2-year]

  8. Target vessel revascularization [At 2-year]

  9. Target lesion revascularization [At 2-year]

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with intermediate coronary artery stenosis (visually 50-90% diameter stenosis) who decided to undergoing a RFR-guided coronary intervention according to clinical necessity

  • Patients who voluntarily decided to participate in this study and signed informed consent

Exclusion Criteria:
  • Severe left ventricular systolic dysfunction (LVEF <30%)

  • Cardiogenic shock

  • Culprit vessel in acute coronary syndrome

  • Donor vessel to supply chronic total occlusion lesion of non-target vessel

  • Symptomatic valvular heart disease or cardiomyopathy

  • Hemodynamic instability at the time of intervention (heart rate <50 beats per minute, systolic blood pressure <90mmHg)

  • Previous CABG with patent grafts to the interrogated vessel

  • Pregnancy or breastfeeding

  • Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sejong general hospital, 91-121 Sosa 2-Dong, Sosa-Gu Bucheon Gyeonggi-do Korea, Republic of 14574

Sponsors and Collaborators

  • Sejong General Hospital
  • Wonju Severance Christian Hospital
  • Hospital San Carlos, Madrid
  • Seoul St. Mary's Hospital
  • Dong-A University Hospital
  • Gyeongsang National University Hospital
  • Soon Chun Hyang University
  • Keimyung University Dongsan Medical Center
  • Ulsan University Hospital
  • Seoul National University Bundang Hospital
  • Kosin University Gospel Hospital
  • Pusan National University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hyun Jong Lee, MD, PhD, Sejong General Hospital
ClinicalTrials.gov Identifier:
NCT06075160
Other Study ID Numbers:
  • COMFORT Vesion 2.6
First Posted:
Oct 10, 2023
Last Update Posted:
Oct 10, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hyun Jong Lee, MD, PhD, Sejong General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 10, 2023